3043 completed, 603 unknown, 468 terminated, 445 recruiting. 5187 Phase 3, 747 Phase 2.
Follow Urogenital Diseases: new trials by email Literature Review of Urogenital Diseases trials Research Report on Urogenital Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss 200mg mifepristone and 800mg misoprostol - Early Pregnancy Loss | Phase 3 | Not yet recruiting | University of Pennsylvania | 1000 | 2027-07-01 | 2026-10-09 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Not yet recruiting | ShangHai Ji Ai Genetics & IVF Institute | 204 | 2027-06-01 | 2026-11-09 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Prediction and Prevention of Bloodstream Infections After Kidney Transplantation Pivmecillinam, Placebo - Kidney Transplant Infection, Bloodstream Infection | Phase 3 | Not yet recruiting | Susanne Dam Nielsen, MD, DMSc | 180 | 2027-01-01 | 2026-10-16 |
| Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children Zopapogene imadenovec-drba - Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis | Phase 3 | Not yet recruiting | Precigen, Inc | 15 | 2026-12-31 | 2026-10-28 |
| Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial A package of oral health interventions, including a daily antiseptic oral rinse (alcohol-free cetylpyridinium chloride (0.075%)) - Preterm Birth, Low Birth Weight | Phase 3 | Not yet recruiting | Johns Hopkins Bloomberg School of Public Health | 2280 | 2026-12-31 | 2026-10-30 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer Transurethral Resection of Bladder Tumor, Sequential Systemic Chemotherapy, radiotherapy - Bladder Cancer, TURBT | Phase 3 | Not yet recruiting | Assiut University | 71 | 2026-12-01 | 2026-11-03 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Pregnancy Loss Vaginal Micronized Progesterone (Progesterone Besins), Enoxaparin (Clexane) - Pregnancy Loss, Pregnancy Loss, Early | Phase 3 | Not yet recruiting | General University Hospital, Prague | 268 | 2026-12-01 | 2026-10-28 |
| Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority Trial Fosfomycin-trometamol (FT), Alternative antibiotic treatment - Escherichia Coli Infection, Elderly Women | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 312 | 2026-12-01 | 2026-11-10 |
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-12-01 | 2026-11-09 |
| A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women Doxycycline hyclate, Standard of Care for STI prevention - Sexually Transmitted Infection (STI), Gonorrhea | Phase 3 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 580 | 2026-11-30 | 2026-10-20 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
Showing 20 of 5187. Sign in to see all of them.
HIV Infections (600) · Prostatic Neoplasms (594) · Renal Insufficiency, Chronic (355) · Acquired Immunodeficiency Syndrome (269) · Ovarian Neoplasms (262) · Uterine Cervical Neoplasms (199) · Infertility (196) · Kidney Failure, Chronic (196) · Premature Birth (180) · Urinary Bladder Neoplasms (166) · Renal Insufficiency (147) · Kidney Diseases (123) · Carcinoma, Renal Cell (122) · Neoplasms (113) · Erectile Dysfunction (111)
Female Urogenital Diseases and Pregnancy Complications (3375) · Genital Diseases (2912) · Female Urogenital Diseases (2892) · Male Urogenital Diseases (2730) · Urologic Diseases (1788) · Neoplasms (1599) · Pathological Conditions, Signs and Symptoms (1599) · Neoplasms by Site (1519) · Urogenital Neoplasms (1500) · Pathologic Processes (1150) · Kidney Diseases (1149) · Infections (1081) · Genital Diseases, Female (1044) · Genital Diseases, Male (905)
Paclitaxel (172) · Carboplatin (136) · Cisplatin (136) · Radiotherapy (98) · Prednisone (95) · Docetaxel (86) · Gemcitabine (85) · Lamivudine (71) · Bevacizumab (68) · Ritonavir (67) · Sodium Chloride (67) · Zidovudine (67) · Saline Solution (63) · efavirenz (61) · Metformin (60)
Merck Sharp & Dohme LLC (114) · National Institute of Allergy and Infectious Diseases (NIAID) (109) · GlaxoSmithKline (93) · Bayer (65) · Pfizer (55) · AstraZeneca (54) · ViiV Healthcare (51) · Eli Lilly and Company (49) · Amgen (47) · Ain Shams University (46) · Ferring Pharmaceuticals (46) · Assistance Publique - Hôpitaux de Paris (43) · Novartis Pharmaceuticals (43) · Hoffmann-La Roche (42) · Bristol-Myers Squibb (38)
United States (2059) · Canada (813) · France (760) · Spain (676) · Italy (667) · United Kingdom (654) · Germany (642) · China (526) · Belgium (488) · Poland (459) · Australia (457) · Netherlands (407) · South Korea (403) · Brazil (376) · Japan (344)
Seetha Shankaran, MD (16)
PMID 41276263, PMID 37185961, PMID 36005278, PMID 40576086, PMID 39356039, PMID 37146227, PMID 37160401, PMID 39513526, PMID 36791280, PMID 35224730, PMID 37407274, PMID 38299639, PMID 34350976, PMID 38770818, PMID 34778952, PMID 35947046, PMID 37916745, PMID 34878624, PMID 38682786, PMID 27238653, PMID 27422279, PMID 28410911, PMID 37651553, PMID 40966692, PMID 19935017, PMID 21059176, PMID 24119319, PMID 24722180, PMID 26972555, PMID 29272162, PMID 32184277, PMID 33270906, PMID 33526329, PMID 35170751, PMID 35224732, PMID 36884035, PMID 37872654, PMID 37888839, PMID 38320143, PMID 39324693, PMID 39607014, PMID 40526444, PMID 23343061, PMID 23343062, PMID 25592642, PMID 25968836, PMID 26299520, PMID 26991902, PMID 29476499, PMID 32621325
2023 (82), 2017 (49), 2016 (43), 2018 (43), 2008 (40), 2014 (37), 2025 (36), 2015 (31), 2009 (29), U10CA180868 (25), 2019 (24), 2004 (18), U10HD021385 (17), U10CA027469 (16), 2005 (15)